How to buy Protalix Biotherapeutics stock (PLX)

Protalix Biotherapeutics is a biotechnology business based in the US. Protalix Biotherapeutics shares (PLX) are listed on the NYSE MKT and all prices are listed in US Dollars. Its last market close was $1.83 – an increase of 3.98% over the previous week. Protalix Biotherapeutics employs 208 staff and has a trailing 12-month revenue of around $38.1 million.

Our top picks for where to buy Protalix Biotherapeutics stock

Buy Protalix Biotherapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Protalix Biotherapeutics stock price (NYSE MKT: PLX)

Use our graph to track the performance of PLX stocks over time.

Protalix Biotherapeutics shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$1.83
52-week range	$0.82 - $1.85
50-day moving average more info button	$1.46
200-day moving average more info button	$1.21
Wall St. target price	$14.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.15

Is it a good time to buy Protalix Biotherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Protalix Biotherapeutics price performance over time

Historical closes compared with the close of $1.78 from 2024-12-26

1 week (2024-12-20)	1.14%
1 month (2024-11-27)	5.33%
3 months (2024-09-27)	69.52%
6 months (2024-06-28)	52.14%

1 year (2023-12-28)	-1.11%
2 years (2022-12-28)	47.11%
3 years (2021-12-28)	104.46%
5 years (2019-12-27)	2.79

Protalix Biotherapeutics financials

Revenue TTM	$38.1 million
Gross profit TTM	$28 million
Return on assets TTM	-10.27%
Return on equity TTM	-43.49%
Profit margin	-38.62%
Book value	$0.46
Market Capitalization more info button	$131.1 million

TTM: trailing 12 months

Protalix Biotherapeutics share dividends

We're not expecting Protalix Biotherapeutics to pay a dividend over the next 12 months.

Have Protalix Biotherapeutics's shares ever split?

Protalix Biotherapeutics's shares were split on a 1:10 basis on 19 December 2019 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Protalix Biotherapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Protalix Biotherapeutics shares which in turn could have impacted Protalix Biotherapeutics's share price.

Protalix Biotherapeutics share price volatility

Over the last 12 months, Protalix Biotherapeutics's shares have ranged in value from as little as $0.8214 up to $1.85. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Protalix Biotherapeutics's is 0.672. This would suggest that Protalix Biotherapeutics's shares are less volatile than average (for this exchange).

Protalix Biotherapeutics overview

Protalix BioTherapeutics, Inc. , a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S. p. A.

Frequently asked questions

What percentage of Protalix Biotherapeutics is owned by insiders or institutions?
Currently 14.534% of Protalix Biotherapeutics shares are held by insiders and 5.198% by institutions. How many people work for Protalix Biotherapeutics?
Latest data suggests 208 work at Protalix Biotherapeutics. When does the fiscal year end for Protalix Biotherapeutics?
Protalix Biotherapeutics's fiscal year ends in December. Where is Protalix Biotherapeutics based?
Protalix Biotherapeutics's address is: Science Park, Karmiel, Israel, 2161401 What is Protalix Biotherapeutics's ISIN number?
Protalix Biotherapeutics's international securities identification number is: US74365A3095 What is Protalix Biotherapeutics's CUSIP number?
Protalix Biotherapeutics's Committee on Uniform Securities Identification Procedures number is: 74365A309